Literature DB >> 27566470

Racial Disparities in Prostate Cancer Mortality in the 50 Largest US Cities.

Maureen R Benjamins1, Bijou R Hunt2, Sarah M Raleigh3, Jana L Hirschtick4, Michelle M Hughes5.   

Abstract

INTRODUCTION: This paper presents race-specific prostate cancer mortality rates and the corresponding disparities for the largest cities in the US over two decades.
METHODS: The 50 largest cities in the US were the units of analysis. Data from two 5-year periods were analyzed: 1990-1994 and 2005-2009. Numerator data were abstracted from national death files where the cause was malignant neoplasm of prostate (prostate cancer) (ICD9=185 and ICD10=C61). Population-based denominators were obtained from US Census data. To measure the racial disparity, we calculated non-Hispanic Black: non-Hispanic White rate ratios (RRs), rate differences (RDs), and corresponding confidence intervals for each 5-year period. We also calculated correlation and unadjusted regression coefficients for 11 city-level variables, such as segregation and median income, and the RDs.
RESULTS: At the final time point (2005-2009), the US and all 41 cities included in the analyses had a RR greater than 1 (indicating that the Black rate was higher than the White rate) (range=1.13 in Minneapolis to 3.24 in Los Angeles), 37 of them statistically significantly so. The US and 26 of the 41 cities saw an increase in the Black:White RR between the time points. The level of disparity within a city was associated with the degree of Black segregation.
CONCLUSION: This analysis revealed large disparities in Black:White prostate cancer mortality in the US and many of its largest cities over the past two decades. The data show considerable variation in the degree of disparity across cities, even among cities within the same state. This type of specific city-level data can be used to motivate public health professionals, government officials, cancer control agencies, and community-based organizations in cities with large or increasing disparities to demand more resources, focus research efforts, and implement effective policy and programmatic changes in order to combat this highly prevalent condition.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Big cities; Epidemiology; Mortality; Prostate cancer; Racial disparities

Mesh:

Year:  2016        PMID: 27566470     DOI: 10.1016/j.canep.2016.07.019

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  13 in total

1.  Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study.

Authors:  Karen M Freund; Jennifer S Haas; Stephenie C Lemon; Karen Burns White; Nicole Casanova; Laura S Dominici; John K Erban; Rachel A Freedman; Ted A James; Naomi Y Ko; Amy M LeClair; Beverly Moy; Susan K Parsons; Tracy A Battaglia
Journal:  Cancer       Date:  2019-08-26       Impact factor: 6.860

2.  Housing discrimination and racial cancer disparities among the 100 largest US metropolitan areas.

Authors:  Kirsten M M Beyer; Purushottam W Laud; Yuhong Zhou; Ann B Nattinger
Journal:  Cancer       Date:  2019-07-09       Impact factor: 6.860

3.  Psychosocial Stress, Glucocorticoid Signaling, and Prostate Cancer Health Disparities in African American Men.

Authors:  Leanne Woods-Burnham; Laura Stiel; Shannalee R Martinez; Evelyn S Sanchez-Hernandez; Herbert C Ruckle; Frankis G Almaguel; Mariana C Stern; Lisa R Roberts; David R Williams; Susanne Montgomery; Carlos A Casiano
Journal:  Cancer Health Disparities       Date:  2020

4.  Prostate cancer upgrading and adverse pathology in Hispanic men undergoing radical prostatectomy.

Authors:  Helen Y Hougen; Oleksii A Iakymenko; Sanoj Punnen; Chad R Ritch; Bruno Nahar; Dipen J Parekh; Oleksandr N Kryvenko; Mark L Gonzalgo
Journal:  World J Urol       Date:  2022-06-10       Impact factor: 3.661

5.  The Influence of Ethnic Heterogeneity on Prostate Cancer Mortality After Radical Prostatectomy in Hispanic or Latino Men: A Population-based Analysis.

Authors:  Maria C Velasquez; Felix M Chinea; Deukwoo Kwon; Nachiketh Soodana Prakash; Marcelo P Barboza; Mark L Gonzalgo; Chad R Ritch; Alan Pollack; Dipen J Parekh; Sanoj Punnen
Journal:  Urology       Date:  2018-04-06       Impact factor: 2.649

6.  The 22Rv1 prostate cancer cell line carries mixed genetic ancestry: Implications for prostate cancer health disparities research using pre-clinical models.

Authors:  Leanne Woods-Burnham; Anamika Basu; Christina K Cajigas-Du Ross; Arthur Love; Clayton Yates; Marino De Leon; Sourav Roy; Carlos A Casiano
Journal:  Prostate       Date:  2017-10-14       Impact factor: 4.012

7.  Involvement of estrogen receptor β in androgen receptor-induced growth inhibition in prostate cancer PC-3 cells.

Authors:  Long Xiao; Minhui Xiao; Linbo Gao; Wanchao Xu
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

8.  Incidence of adrenal gland tumor as a second primary malignancy: SEER-based study.

Authors:  Wafaa M Rashed; Anas M Saad; Muneer J Al-Husseini; Ahmed Mahmoud Galal; Assem Mohamed Ismael; Ahmed M Al-Tayep; Ayman El Shafie; Mahmoud Ahmed Ali; Ahmed Samir Alfaar
Journal:  Endocr Connect       Date:  2018-08-23       Impact factor: 3.335

9.  Trends in mortality among Black and White men with prostate cancer in Massachusetts and Pennsylvania: Race and neighborhood socioeconomic position.

Authors:  Hari S Iyer; Scarlett L Gomez; Jarvis T Chen; Quoc-Dien Trinh; Timothy R Rebbeck
Journal:  Cancer       Date:  2021-04-02       Impact factor: 6.921

10.  Glucocorticoids Induce Stress Oncoproteins Associated with Therapy-Resistance in African American and European American Prostate Cancer Cells.

Authors:  Leanne Woods-Burnham; Christina K Cajigas-Du Ross; Arthur Love; Anamika Basu; Evelyn S Sanchez-Hernandez; Shannalee R Martinez; Greisha L Ortiz-Hernández; Laura Stiel; Alfonso M Durán; Colwick Wilson; Susanne Montgomery; Sourav Roy; Carlos A Casiano
Journal:  Sci Rep       Date:  2018-10-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.